trending Market Intelligence /marketintelligence/en/news-insights/trending/vwSzBs9h8N6d0LfflJyqjQ2 content esgSubNav
In This List

Bristol-Myers therapy wins US FDA nod to treat blood cancer subtype in children


Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Bristol-Myers therapy wins US FDA nod to treat blood cancer subtype in children

Bristol-Myers Squibb Co. said the U.S. Food and Drug Administration approved a combination of its cancer drug Sprycel and chemotherapy to treat certain children with a type of blood cancer.

Philadelphia chromosome-positive acute lymphoblastic leukemia, or Ph+ ALL, is a rare subtype of acute lymphoblastic leukemia. In Ph+ ALL, patients have a chromosome alteration that causes the BCR-ABL gene to mutate and produce a protein that leads to the growth and reproduction of cancer cells.

SNL Image

Sprycel, or dasatinib, is now approved to treat children one year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy.

The approval, which was granted after priority review by the FDA, is based on data from a phase 2 study in 78 patients with showed that event-free survival, the length of time after start of Sprycel treatment to lack of remission or certain complications including death, was 64.1% after three years.

Sprycel is already approved to treat children with Philadelphia chromosome-positive chronic myeloid leukemia, or Ph+ CML, in chronic phase.

The drug is also approved to treat adult patients with Ph+ CML in chronic phase; with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib; and with Ph+ ALL with resistance or intolerance to prior therapy.